ABSTRACT The mechanism of association and the organization of human fibrin were studied by using affinity chromatography. Insolubilized fibrinogen, fibrin monomer, and crosslinked fibrin were used to localize the binding sites on fibrinogen and fibrin derivatives. Four different polymerization sites have been distinguished. A binding site ("a"), available without thrombin action, is present on the fibrinogen fragment D domain. The complementary ("A") is inoperative in fibrinogen and requires thrombin for activation; it is located on the fibrinogen NH2-terminal domain. A third polymerization site ("b") appears to be formed by the alignment of the fragment D domains on two fibrin monomer molecules upon polymerization; this site functions without thrombin mediation and the alignment is stabilized by the Factor XIIIa-catalyzed crosslink bonds. The "b" site is complementary to another thrombinactivated site ("B") on the fibrinogen NHllterminal domain. The two thrombin activable sites, "A" and "B", are distinguishable, although they are located in the same fibrinogen domain. Activation of fibrinogen by thrombin causes the release of fibrinopeptides A and B, followed by the formation of an ordered fibrin polymer, probably due to the association of complementary binding sites (1 The purpose of the present work was to investigate the interactions of fibrinogen, fibrin, and their derivatives with short fibrin oligomers. The steric alignment of the fibrin monomer molecules appears to be an important event in the generation of a new binding site. The aligned fibrin monomers were covalently stabilized by Factor XIIIa-induced crosslinking. The prepared insolubilized crosslinked fibrin oligomers were utilized in conjunction with insolubilized fibrinogen and fibrin monomer to examine the availability of binding sites on fibrinogen and fibrin derivatives, and were used to localize and characterize fibrin polymerization sites.
fibrinogen NH2-terminal domain. A third polymerization site ("b") appears to be formed by the alignment of the fragment D domains on two fibrin monomer molecules upon polymerization; this site functions without thrombin mediation and the alignment is stabilized by the Factor XIIIa-catalyzed crosslink bonds. The "b" site is complementary to another thrombinactivated site ("B") on the fibrinogen NHllterminal domain. The two thrombin activable sites, "A" and "B", are distinguishable, although they are located in the same fibrinogen domain. Activation of fibrinogen by thrombin causes the release of fibrinopeptides A and B, followed by the formation of an ordered fibrin polymer, probably due to the association of complementary binding sites (1) . Recent investigations have focused on defining areas of the fibrin monomer molecule that participate in polymerization by identifying binding properties of degradation products of fibrinogen or fibrin. Binding sites have been localized on fragment D* and in the NH2-terminal domain of fibrin (2) (3) (4) (5) . It was suggested that the COOH terminus of the fragment D y-chain remnant contains a binding region (2) . The localization of the NH2-terminal binding site is being actively pursued and questions about whether the site is monoor bivalent and about the role of the fibrinopeptides are unresolved. Accumulating data support a hypothesis that the removal of fibrinopeptides A and B activates separate binding sites on the NH2-terminal region of the fibrinogen molecule (6) (7) (8) (9) . These sites are not equivalent because the site revealed by the loss of fibrinopeptide A is sufficient to induce polymerization of fibrin but the site activated by the loss of fibrinopeptide B will not initiate clotting under physiological conditions.
We have shown that the binding sites on the NH2-terminal and fragment D domains of the fibrinogen molecule can be examined in a soluble system (10) . Binding sites localized on fragments E1 and E2t were complementary to those on fragment DD*, but did not bind to fragment D from fibrinogen or from noncrosslinked fibrin. This indicated that fragments E1 and E2 contained sites specifically complementary to the aligned domains of the two fragment D moieties in fragment DD. Fragment DD also complexed with fibrinogen, fragments X and Y, and NH2-terminal disulfide knot (NDSK) after these species were treated with thrombin (10) .
The purpose of the present work was to investigate the interactions of fibrinogen, fibrin, and their derivatives with short fibrin oligomers. The steric alignment of the fibrin monomer molecules appears to be an important event in the generation of a new binding site. The aligned fibrin monomers were covalently stabilized by Factor XIIIa-induced crosslinking. The prepared insolubilized crosslinked fibrin oligomers were utilized in conjunction with insolubilized fibrinogen and fibrin monomer to examine the availability of binding sites on fibrinogen and fibrin derivatives, and were used to localize and characterize fibrin polymerization sites.
MATERIALS (14) . NDSK was isolated from cyanogen bromide-degraded fibrinogen by a modification of the method of Blomback and colleagues (10, 15) . Fragment A (16) was purified by column gel filtration on Sepharose CL-6B (17) .
Fragment DD, the (DD)E complex, and a polymer remnants were isolated by gel filtration on Sepharose CL-6B (18, 19) . Fragments El, E2, and E3 were isolated by a combination of column gel filtration on Sepharose CL-6B and ion exchange chromatography on DE-52 cellulose (10) . Thrombin treatment of fragments was carried out (5), after which the thrombin was inhibited by the addition of 100 antithrombin units of hirudin per unit of thrombin prior to binding studies. Binding of thrombin-treated fragments to Seph-Fbg was done in the presence of 25 antithrombin units/ml of hirudin.
Polyacrylamide gel electrophoresis was done on 7% polyacrylamide gels (0.5 X 9 cm) containing 0.1% sodium dodecyl sulfate (20) and on Tris glycine (9%) gels (21) . Staining was done with Coomassie brilliant blue and gels were scanned with a densitometer (Densicord 552, Photovolt, New York).
Quantitative protein determination was carried out by direct ultraviolet spectrophotometry at 280 nm (absorption coefficients at 1 mg/ml; fibrinogen, 1 A number of derivatives can be formed after the crosslinking reaction of Seph-FM loaded with fibrinogen. In the original Seph-FM pool, 17% of the attached material, rather than 100%, was functionally active; however, after incubation with fibrinogen, probably no free active fibrin monomer was available. An insolubilized fibrin dimer was probably formed but could be further crosslinked to similar species. Therefore, the Seph-XF preparation probably contained a majority of unreactive insolubilized fibrin monomer and some species of either fibrin dimers, trimers, or tetramers. To differentiate among the latter possibilities, the ratio of the Fyy to y chains was cal- Biochemistry: Olexa and (25) . It has been speculated (26) that the two processes could be regulated by the differential release rates of fibrinopeptides A and B by thrombin. Recent reports favor this concept (6-9) and postulate that two sets of binding sites may be engaged to direct the linear and lateral association of the monomers, respectively.
The data presented in Table 1 with Seph-Fbg and Seph-FM further support this concept and demonstrate the presence of polymerization sites that are complementary to each other. One binding site is associated with the fragment D moiety present in fragments derived from the COOH terminus of fibrinogen (27, 28) . The binding site, called "a" in Fig. 2 , is unaffected by thrombin and is exposed in fibrinogen, as shown by the binding of fibrinogen to Seph-FM as well as in several studies using different systems (2-5, 10). The complementary binding site marked "A" in Fig. 2 is not available on fibrinogen and its derivatives containing the NH2-terminal region of the parent molecule, but it is exposed or activated by thrombin. The conclusion that thrombin activates a polymerization site in the NH2-terminal region of fibrinogen corroborates observations in other investigations (2-10, 33). Thrombin-treated NDSK bound to Seph-Fbg, Seph-FM, and Seph-XF, confirming the presence of a binding site on the NH2-terminal region. Before thrombin treatment there was some binding of NDSK to the resins, suggesting the presence of another binding site either specific or exposed after denaturation with formic acid used for the preparation of NDSK (15) .
Our earlier observation on the binding properties of fragments E1 and E2 isolated from a plasmic digest of human crosslinked fibrin (10) demonstrated their affinity for fragment DD but not for fragments D. This binding difference suggested that crosslinked fibrin may carry additional affinitive regions. In order to test this hypothesis a short oligomer, consisting of approximately four Factor XIIIa-crosslinked fibrin monomer units attached covalently to Sepharose (Fig. 1) , has been synthesized. This material provided a matrix resembling a strand of crosslinked fibrin and as such offered an experimental system enabling binding studies of fibrinogen and fibrin derivatives to an early antecedent of a fibrin clot.
Blomback and colleagues (9) proposed that, in addition to the primary polymerization site revealed by the release of fibrinopeptide A, the release of fibrinopeptide B activates a second polymerization domain that interacts with another site in a neighboring molecule. These authors inferred that linear polymerization takes place through two sets of complementary binding sites. Experimental basis for this is a delay of fibrinogen Detroit (34) polymerization until removal of approximately 10% of fibrinopeptide B. The data in the present work indicate that the second set of polymerization sites "B" and "b", the former perhaps revealed by the loss of fibrinopeptide B, are not responsible for end-to-end alignment of fibrin monomer molecules but contribute to the lateral aggregation of fibrin strands (Fig. 2) . The crosslink bonds between two y chains of the neighboring fibrin monomer molecules either may participate in the binding site or may stabilize the sites on aligned fibrin monomer molecules. The "b" site is complementary to the thrombin-activated site on the NH2-terminal domain of fibrin monomer "B." The two "B" sites on the second (upper) layer of fibrin bind to the "bb" sites on the first (lower, shaded) layer. Meanwhile, the alignment of the fibrin monomer molecules on the second (upper) layer results in the formation of "bb" binding sites that will enable the addition of a third layer of fibrin. Therefore, the binding of "A" to "a" sites promotes linear polymerization of the fibrin monomer molecules as well as fibrin strand branching, whereas the binding of "BB" to "bb" sites allows lateral aggregation. The interaction of these four sites represents a major mechanism for fibrin polymerization; however, other interactions such as those responsible for the ordered precipitation of fibrinogen by protamine sulfate may also play a role.
Affinity chromatography on Seph-XF (Table 1) gave the essential information about the additional fibrin polymerization sites. The binding of fragments E1 and E2 to Seph-XF but not to Seph-Fbg or Seph-FM suggested that the fragments E contain binding sites ("B" in Fig. 2) complementary to a site on polymerized fibrin that is not available on fibrinogen or fibrin monomer. This site ("b" in Fig. 2 ) is also operative in fragment DD because fragments E1 and E2 bound in solution with fragment DD but not with fragment D (10). The binding site "b" may be at or near the Factor XIIIa-induced crosslink bonds or these covalent bonds may align and stabilize the sites on the two fragment D moieties. Because fragments E1 or E2 bound only to the aligned fragment D domains, but not to single fragment D molecules, this suggests that there is an order of association of the polymerization sites. The binding between sites "A" and "a" would occur as soon as thrombin exposes site "A" (Fig. 2) . However, the association between sites "B" and "b" cannot occur even after the cleavage of both fibrinopeptides. The critical step is the alignment of the fragment D domains in the fibrin fiber, which generates "b" binding sites.
Biochemistry: Olexa and 
The data presented in this work indicate that there are four different binding sites involved in fibrin polymerization and that there is an order of association of these sites (Fig. 2) . First, a thrombin-activated site "A" is located on the NH2-terminal region of fibrinogen, exemplified by the binding of thrombin-treated fragments X and Y and NDSK to Seph-Fbg (Table  1) . Second, there is a site "a" on the COOH terminus of fibrinogen localized on the fragment D domain that is not affected by thrombin and is complementary to the "A" site, shown by the binding of fibrinogen fragments X, Y, and D to Seph-FM but not to Seph-Fbg (Table 1) . Third, the site "b" specific to polymerized fibrin is formed by the aligned fragment D moieties, exemplified by the binding of Fragments E1 and E2 to Seph-XF but not to Seph-FM (Table 1) . Fourth, there is a thrombin-activated site "B" on the NH2-terminal region localized on fragments E1 and E2 and NDSK that is complementary to the "b" site newly formed in polymerized fibrin. This latter site is also shown by the greater increase in binding of fragments X and Y to Seph-XF than to Seph-FM after thrombin treatment ( Table 1 ). The sites "A" and "B" can be distinguished, although both are located on the NH2-terminal region of fibrinogen and both are thrombin activated. Thrombin-treated NDSK contains both "A" and "B" sites, because this molecule binds to Seph-FM and Seph-XF as well as forms a complex with fragment DD in solution (10) . However, fragments E1 and E2 contain the "B" site whereas the "A" site is not available, perhaps due to proteolytic cleavages by plasmin, because these fragments cannot bind to Seph-Fbg or Seph-FM or form a complex in solution with fragment D. The sites "a" and "b" can be distinguished because "a" is present on the COOH-terminal region of fibrinogen in fragment D and "b" is present on the aligned fragment D regions of fibrin (fragment DD). These results support a model of fibrin polymerization (outlined in Fig. 2 ) that describes not only the linear elongation of fibrin strands but also the lateral aggregation of strands of fibrin. Because there are two different polymerization sites activated by thrombin, one probably involved in strand elongation and the other in lateral aggregation, it is possible that the former site is exposed by the removal of fibrinopeptide A and the latter, by removal of fibrinopeptide B as suggested by Blombick and colleagues (9) . The slow rate of fibrinopeptide B removal by thrombin in the liquid phase would serve to ensure the orderly association of polymerization sites with predominant formation of linear polymers of fibrin under physiological conditions.
